Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study should estimate the dose proportionality of BAY94-8862 IR tablets.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bayer

Criteria

Inclusion Criteria:

• Healthy male subject

• Age: 18 to 46 years (inclusive) at the first screening examination

• Ethnicity: White

• Body mass index (BMI): >= 18 and <= 29.9 kg / m²

Exclusion Criteria:

• Clinically relevant findings in the ECG (electrocardiogram) such as a second- or third-degree AV block, prolongation of the QRS complex over 120 msec

• Systolic blood pressure below 100 or above 140 mmHg

• Diastolic blood pressure below 50 or above 90 mmHg

• Heart rate below 50 or above 95 beats/ min

• Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), human immune deficiency virus antibodies (anti-HIV 1+2)

• Participation in another clinical study during the preceding 3 months (Last Treatment from previous study to First Treatment of new study)